Findings

What do systematic reviews say?

1 questions · 1 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 1 · 100%High 0 · 0%

Target of rapamycin inhibitors (TOR‐I) vs calcineurin inhibitors (CNI): secondary outcomes

Lymphoma/PTLD · primary immunosuppression in kidney transplant recipients

Target of rapamycin inhibitors (TOR‐I) showed no clear difference in lymphoma/PTLD compared with calcineurin inhibitors (CNI): secondary outcomes (moderate certainty).

1 finding from 1 review

Target of rapamycin inhibitors (TOR‐I; sirolimus and everolimus) for primary immunosuppression in kidney transplant… 2019 · Cochrane Headline outcomes only
RR 2.47 [0.78, 7.86]
8 studies · 2537 participants
Moderate